Able to discontinue all anticancer therapies  weeks prior to study start
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics). Patients who have received prior endocrine therapy for fertility purposes will be eligible
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics)
Subjects currently receiving other anticancer therapies.
Patients currently receiving medical anticancer therapies or who have received medical anticancer therapies within  weeks of the start of study drug (including chemotherapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  days of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.); steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapy
Patients currently receiving anticancer therapies or who have received anticancer therapies (including chemotherapy and targeted therapy) within  weeks ( days) prior to study day are excluded. Patients who have completed palliative radiation therapy more than  days prior to the first dose of the combination ipilimumab plus nivolumab are eligible.
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks ( days) from enrollment into this study (including chemotherapy and targeted therapy) are excluded; also, patients who have completed palliative radiation therapy more than  days prior to the first dose of MGCD are eligible
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of the investigational therapy (including chemotherapy, radiation therapy, antibody based therapy)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks including chemotherapy, radiation therapy, antibody based therapy, etc.
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, antibody based therapy, e.g. lapatinib, bevacizumab, erlotinib, imatinib, that are sometimes offered on a compassionate-use basis to NF patients)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving non-hormonal anticancer therapies or who have received non-hormonal anticancer therapies within  weeks from day  of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received exclusively for bony metastases and the interval between completion of radiation treatments and the first infusion of study drug is less than  days; hormonal therapies are not excluded
Patients currently receiving anticancer therapies or who have received anticancer therapies within  days from day  of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received for bone metastases (palliative radiation), the minimum interval between completion of radiation treatment and first dose of study drug is  days
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies =<  weeks prior to registration (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of everolimus and LDE (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug including chemotherapy, biologics, targeted therapies, or immunologics
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug or patients receiving prior treatment with investigational drugs  weeks of the start of study drug
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Anticancer chemotherapy or immunotherapy during the study or within less than  half-lives for anticancer chemotherapy or  weeks for antibody therapies ( weeks for leukemia patients) prior to start of study drug.
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc., but not including somatostatin analogues, e.g., octreotide)
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving any other anticancer therapies;
Patients currently receiving anticancer therapies or who have received anticancer therapies within  weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc)
Patients currently receiving anticancer therapies (except biphosphonate, denosumab);